Application

17932509 · PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF

Filed 2022-09-15 · Abandoned The official file ↗ · Art unit 1627 · Examiner Dawanna Shar-Day White Typical · CPC A61K 31/505 · Acetylon Pharmaceuticals, Inc. · FOLEY HOAG, LLP (General)

Office actions

first was Restriction requirement

RCEs

appealed

To first action

13.7 mo

to disposition 41.8 mo

Statutes raised

103 112 DP

2 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.